Effect of Macugen (Pegaptanib) on Surgical Outcomes and Growth Factors Including Vascular Endothelial Growth Factor (VEGF) Levels in Patients With Proliferative Diabetic Retinopathy (PDR) and Clinically Significant Diabetic Macular Edema (CSDME).
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2012
At a glance
- Drugs Pegaptanib (Primary)
- Indications Diabetic macular oedema; Diabetic retinopathy
- Focus Pharmacodynamics; Pharmacokinetics
- 07 Jun 2017 Biomarkers information updated
- 03 Nov 2009 New trial record.